atazanavir sulfate has been researched along with Atherosclerosis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hatleberg, CI; Ryom, L; Sabin, C | 1 |
| Ard, KL; Beckman, JA; Milian, J; Prenner, JC; Price, CN; Sax, PE; Solomon, DA; Wood, BR; Zuflacht, JP | 1 |
| Bandera, A; Clerici, M; Fenizia, C; Giannattasio, C; Gori, A; Maloberti, A; Masetti, M; Muscatello, A; Sabbatini, F; Soria, A; Squillace, N; Trabattoni, D | 1 |
| Beckman, JA; Goldfine, AB; Milian, J; Parmer, C; Zuflacht, JP | 1 |
| Ando, A; Baumer, Y; Byron, MM; Chow, D; Kallianpur, KJ; Keating, S; Kohorn, L; Ndhlovu, L; Shikuma, C; Souza, S | 1 |
| Ansart, S; Bellein, V; Bressollette, L; de Saint-Martin, L; Pasquier, E; Perfezou, P; Vallet, S | 1 |
| Chen, L; Ding, H; Gurley, EC; Hu, W; Hylemon, PB; Jarujaron, S; Pandak, WM; Studer, E; Wang, JY; Zhou, H; Zou, T | 1 |
1 review(s) available for atazanavir sulfate and Atherosclerosis
| Article | Year |
|---|---|
Cardiovascular risks associated with protease inhibitors for the treatment of HIV.
Topics: Animals; Atazanavir Sulfate; Atherosclerosis; Cardiovascular Diseases; Darunavir; Dyslipidemias; Heart Disease Risk Factors; HIV Infections; HIV Protease Inhibitors; Humans; Randomized Controlled Trials as Topic | 2021 |
2 trial(s) available for atazanavir sulfate and Atherosclerosis
| Article | Year |
|---|---|
Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Biomarkers; Cross-Sectional Studies; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxidative Stress; Risk Factors; Viral Load | 2017 |
Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus.
Topics: Adult; Antioxidants; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Blood Pressure; Cardiovascular System; Cholesterol, LDL; Diabetes Mellitus, Type 1; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Oxidative Stress; Risk Factors; Vasodilation | 2015 |
4 other study(ies) available for atazanavir sulfate and Atherosclerosis
| Article | Year |
|---|---|
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Adhesion Molecules; Endothelial Cells; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Lymphocyte Activation; Male; Prospective Studies; Pulse Wave Analysis; Random Allocation; Ritonavir | 2018 |
Atazanavir use and carotid intima media thickness progression in HIV: potential influence of bilirubin.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Carotid Intima-Media Thickness; Female; HIV Infections; Humans; Male; Retrospective Studies | 2016 |
Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atherosclerosis; Cohort Studies; Female; France; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Tunica Intima; Tunica Media | 2010 |
HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR.
Topics: Animals; Antigens, Surface; Atazanavir Sulfate; Atherosclerosis; ELAV Proteins; ELAV-Like Protein 1; Endoplasmic Reticulum; Gene Expression Regulation; HIV Protease Inhibitors; Humans; Interleukin-6; Lentivirus; Macrophages; Mice; Oligopeptides; Pyridines; Risk Factors; RNA-Binding Proteins; Tumor Necrosis Factor-alpha | 2007 |